Takeda's Phase 3 Study Results

Takeda has announced promising results from its Phase 3 studies of Oveporexton, an orexin receptor agonist, showing significant improvements in daily function, cognition, and nighttime sleep for individuals with narcolepsy type 1. These findings were presented at the SLEEP 2026 conference on 15th June.n

Designed to tackle orexin deficiency, Oveporexton, also known as TAK-861, restores orexin signalling that causes narcolepsy type 1. The studies indicate significant enhancements in daily functioning and cognitive abilities while reducing sleep disturbances.n

Principal investigator of the FirstLight study, Dr. Emmanuel Mignot, has remarked, “Oveporexton has demonstrated significant improvement across a broad range of NT1 symptoms, daily functioning, and quality of life.”n

Study Findings and Implicationsn

Conducted globally, the studies FirstLight and RadiantLight were placebo-controlled and involved 273 participants. Results show that Oveporexton significantly improved daily functioning and cognitive symptoms across all doses. Around 70% of patients reported no significant cognitive difficulties, compared to 15% in the placebo group.n

Improvements in nighttime sleep quality were demonstrated in exploratory endpoints, with reduced hallucinations and sleep paralysis. REM sleep patterns of patients on Oveporexton began to resemble those of healthy individuals.n

Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit at Takeda, stated, “With Oveporexton under review by multiple regulatory agencies, we are on the cusp of bringing the first and only orexin agonist to the narcolepsy type 1 community.”n

The United States FDA has accepted the New Drug Application for Oveporexton and granted it Priority Review, with a decision expected in the third quarter of 2026. The drug is also under review in China and Japan, with further submissions planned.n

Significant improvements in six domains of the Functional Impacts of Narcolepsy Instrument were highlighted in Takeda’s studies, including tiredness, cognitive functioning, cataplexy, social activities, everyday activities, and responsibilities. These improvements underscore Oveporexton’s ability to help individuals manage their everyday lives effectively.n

Aiming to redefine the standard of care for narcolepsy type 1, the drug offers patients a potential shift in disease management beyond mere symptom relief. Oveporexton’s capacity to address a broad spectrum of symptoms offers hope to many living with this challenging condition.